Court Ruling in Favor of Aquestive Therapeutics Enjoining Dr. Reddy's Laboratories from Launching its Generic Suboxone Product

Aquestive Granted Preliminary Injunction

WARREN, N.J., July 16, 2018 /PRNewswire/ -- Aquestive Therapeutics ("Aquestive") announces today that the U.S. District Court for the District of New Jersey has granted Aquestive together with Indivior PLKC (LON: INDV) and its U.S. subsidiary, Indivior Inc., a preliminary injunction against Dr. Reddy's Laboratories Ltd. ("DRL"), mandating the restrictions of the previously entered temporary restraining order (TRO) remain in place. The preliminary injunction prevents DRL from using, selling, offering to sell, or importing its generic buprenorphine/naloxone sublingual film until further order of the district court or of the appellate court. At issue in the underlying preliminary injunction proceedings was, among other things, the infringement of U.S. Patent No. 9,931,305 (known as the "305 patent") by DRL.

Keith J. Kendall, CEO of Aquestive, said: "This decision once again demonstrates the significant value our intellectual property has created for Aquestive, its products and our partners." He added, "We continue to believe that DRL's challenge to our patents is without merit."

About Aquestive Therapeutics

Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. For more information, please visit our website,

Media inquiries:
Christopher Hippolyte

Investor inquiries:
Stephanie Carrington

View original content:

SOURCE Aquestive Therapeutics


Back to news